迷迭香作为重度抑郁症患者的辅助治疗：一项随机，双盲，安慰剂对照试验。
摘要来源：
补充Clin ther Clin实践。 2022年11月2日; 49：101685。 EPUB 2022 11月2日。PMID： 36343423 36343423 Sharififar，Gholamreza dehghannoudeh，Farzaneh Jahanbakhsh，Fatemeh Dabaghzadeh
文章隶属关系：Saeed Azizi
摘要：
材料和方法： 图形方法。制备了迷迭香的坚硬明胶胶囊，并评估了它们的理化特性。在这项临床试验中，重度抑郁症患者被随机分为迷迭香和对照组。他们每天两次获得一个迷迭香或安慰剂胶囊，持续8周。 The anxiety subscale of Hospital Anxiety and Depression Scale and Beck Depression Inventory - Second Edition were respectively used to measure the symptoms of anxiety and depression in the patients before initiating the treatment and four and eight weeks after the treatment.
RESULTS: The amount of rosmarinic acid in rosemary was found to be 21.13 ± 0.56 mg/g干植物。与对照组治疗后8周相比，迷迭香组的焦虑症量表和贝克抑郁量表的评分显着下降。记忆改善是有益的一面effect observed in the study.
CONCLUSION: The use of rosemary as an adjunctive therapy could improve the symptoms of anxiety and depression in people with major depression.